Ophthalmic Business News

Pharmaceutical waste in ophthalmic surgical practice accounts for a significant proportion of medical waste per year.

In this episode, Dagny Zhu, MD, and Laura Periman, MD, chat with Kendra Hileman on how to get involved in clinical research.

Restoret showed promising safety and efficacy results at 12 weeks in patients with treatment-naive diabetic macular edema and treatment-naive neovascular age-related macular degeneration, according to a press release from EyeBio.

A phase 3 clinical trial of tivanisiran failed to meet the primary endpoint in the treatment of dry eye disease associated with Sjörgren’s syndrome, according to a press release from Sylentis.

The term “wellness” has become increasingly popular in the general public at large, and within the medical community specifically.

The FDA cleared an investigational new drug application for OK-101 for the treatment of neuropathic corneal pain, according to a press release from Okyo Pharma.

Toku has obtained CE and UKCA marks for its CLAiR technology to assess cardiovascular disease risk using retinal images, according to a press release.

Carl Zeiss Meditec AG reached a settlement in a lawsuit against Topcon over claims of illicitly obtained stolen Zeiss files, including highly confidential information, according to a press release.

Kiora Pharmaceuticals has entered into a strategic agreement that grants Théa Open Innovation development and commercialization rights to KIO-301 for the treatment of degenerative retinal diseases.

The end of the federal student loan payment pause, a reprieve that lasted more than 3 years due to the COVID-19 pandemic, marks a critical juncture for millions of Americans, especially for physicians.